Who funds hypertension research?

We count 52 funded hypertension projects, active between 2021 and 2032, from 5 funders. The most came from Wellcome (11 projects), EU · Health (8 projects) and EU · ERC (7 projects). The median award is $3.1M, across the 48 of 52 projects that list an amount.

Funded projects

52

Funders

5

Median award

$3.1M

Open calls now

0

Top funders of hypertension research

Projects whose title or summary mentions hypertension. Median award: of the projects that list an amount, in US dollars; “—” when fewer than 3 do.

Open hypertension funding calls

No open call mentions hypertension in our listings today. We add new calls twice a day; create a free account to get an alert when one opens.

Funded hypertension projects

A sample, latest start first, at most three per program.

• Understanding intergenerational transmission of poor cardiovascular health in Africa (GenHeart Study)
  Wellcome · £2,581,002 · ends 2032
• Clarifying the Optimal Application of SLT Therapy (COAST) Trial
  NIH · NEI · $3,334,327 · ends 2031
• Obesity, diabetes and hypertension during pregnancy significantly increase morbidity in pregnant women and the risks of metabolic diseases…
  USDA · $630,435 · ends 2031
• WNK-SPAK signaling in the Distal Nephron
  NIH · NIDDK · $3,301,901 · ends 2030
• Role of ferroptosis of oligodendrocytes and vascular endothelial cells in vascular and Alzheimer's Disease related dementia
  NIH · NIA · $3,401,351 · ends 2030
• Examining Effects of Intensive BP Control on MCI/Dementia and Plasma Biomarker Trajectories by AD Pathology: Elucidating neuroprotective effects in the racially and ethnically diverse SPRINT trial
  NIH · NIA · $5,789,766 · ends 2030
• HIV and endothelial function in women of reproductive age (HEART)
  NIH · NHLBI · $3,053,547 · ends 2030
• Gestational hypertension and preeclampsia blood pressure (BP) Treatment goals <140/90 vs. <160/110 mmHg: The GOALPOST Trial
  NIH · NICHD · $3,106,769 · ends 2030
• Examining Effects of Intensive BP Control on MCI/Dementia and Plasma Biomarker Trajectories by AD Pathology: Elucidating neuroprotective effects in the SPRINT trial
  NIH · NIA · $5,003,735 · ends 2030
• Neighborhood and individual environmental risk factors in early life and -omics biomarkers for kidney function trajectories across childhood and adulthood
  NIH · NIEHS · $3,796,422 · ends 2030

How we count

Funded projects come from public award records (NIH RePORTER, NSF, EU CORDIS, UKRI Gateway to Research, Wellcome, the Gates Foundation, DOE, NASA and USDA NIFA) whose title or summary matches “hypertension”. NIH lists each budget year separately; one project counts once. Amounts are as the funder lists them; medians use only projects that list one, in US dollars. Open calls and forecasts are from our listings of October 28, 2026. A project can mention a topic without being mainly about it, so treat the counts as a guide to who funds the area.